- Clinical Experience
- Rheumatology
- Pulmonology
- Ophthalmology
- Nephrology
- Neurology
- Proposed MOA
- Dosing & Duration
- Safety Data
- Acthar Patient Support
- Resources & Videos
Acthar Patient Support is available. Learn more.
Tumlin J, Galphin C, Santos R, Rovin B—Kidney International Reports, 2017
To evaluate the impact of Acthar Gel on proteinuria reduction in a patient population with treatment-resistant FSGS
eGFR=estimated glomerular filtration rate.
*Majority included steroids and calcineurin inhibitor, but also included mycophenolate mofetil and rapamycin alone or in combination.
Other than steroids, listed therapies are not approved for the reduction of proteinuria in NS.
Assessment after 6 months of Acthar Gel monotherapy
*Complete remission: urine protein to creatinine ratio (UPCR) <300 mg/g. Partial remission: 50% reduction in UPCR to <3500 mg/g.
Get the prescription and reimbursement process started
Acthar Gel is indicated for:
Contraindications
Acthar is contraindicated:
Warnings and Precautions
Adverse Reactions
Pregnancy
Please see full Prescribing Information for additional Important Safety Information.
Acthar Gel is indicated for:
Acthar Gel is indicated for:
Contraindications
Acthar is contraindicated:
Warnings and Precautions
Adverse Reactions
Pregnancy
Please see full Prescribing Information for additional Important Safety Information.
Acthar Gel is indicated for:
Contraindications
Acthar is contraindicated:
Warnings and Precautions
Adverse Reactions
Pregnancy
Please see full Prescribing Information for additional Important Safety Information.
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References: